Oral News and Research

RSS

Genta reports net loss of $11.7M for fourth-quarter 2009

Genta Incorporated today reported results for the quarter and year ended December 31, 2009. The Company also provided an overview of recent corporate highlights and anticipated milestones.

29 Mar 2010

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

Rigel Pharmaceuticals, Inc. today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 relating to the license agreement between Rigel and AstraZeneca, the effectiveness of which was contingent on the expiration of the waiting period.

29 Mar 2010

ARYx Therapeutics reports net loss of $5.8M for fourth-quarter 2009

ARYx Therapeutics, Inc. today reported results of operations and provided an update on its products for the fourth quarter and year ended December 31, 2009.

29 Mar 2010

IOF invites for Asia-Pacific Osteoporosis Meeting in Singapore

The International Osteoporosis Foundation (IOF) invites you to attend the first of a new series of meetings - the IOF Regionals: Asia-Pacific Osteoporosis Meeting, to be held in Singapore from December 10-13, 2010.

29 Mar 2010

Cortex signs agreement to sell certain AMPAKINE compounds to Biovail

Cortex Pharmaceuticals, Inc. announced that it has entered into an agreement with Biovail Laboratories International SRL in which Biovail acquired certain AMPAKINE compounds and the rights to the patent filing for respiratory depression and vaso-occlusive crises associated with sickle cell disease.

29 Mar 2010

NZ Doctor struck off for misconduct

While all names have been suppressed to protect the identities of those involved, the case has caught the imagination of the media. “Dr N” who admitted to professional misconduct before the Health Practitioners Disciplinary Tribunal was reported to have appealed to the High Court against being struck off by The Weekend Herald on Saturday. The appeal was unsuccessful.

29 Mar 2010

Cut in Medicare reimbursement to physicians will jeopardize timely surgical care

The results of a new member survey by the nation's Surgical Coalition shows that the more than 21 percent pay cut to physicians that is scheduled to take effect April 1 will make it difficult, if not impossible, for already financially strapped surgical practices to continue to treat Medicare patients. A majority of the more than 14,000 surgeons and anesthesiologists who responded to the survey indicated that they will be forced to make significant changes in their practices if the cut goes into effect and that timely access to surgical care will be jeopardized if Medicare payments continue to decline.

27 Mar 2010

Two EMBEDA video news releases misleading, warns FDA DDMAC

On October 8, 2009, King Pharmaceuticals, Inc. received a Warning Letter from the Division of Drug Marketing, Advertising, and Communications (DDMAC) at the Food and Drug Administration regarding two video news releases - EMBEDA Media backgrounder, and EMBEDA Visual Media Technology, for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use C-II.

27 Mar 2010

Indoor tanning devices: AADA testifies before FDA panel on needed classification changes and calls for ban

American Academy of Dermatology Association (AADA) President and dermatologist William D. James, MD, FAAD, along with other dermatologists and leading researchers today testified before a Food and Drug Administration (FDA) panel considering changes to the current classification of indoor tanning devices. Currently, the FDA classifies indoor tanning devices as Class 1, the category for items that have minimal potential to cause harm to individuals. Items in Class 1 include adhesive bandages and tongue depressors.

27 Mar 2010

Oral Health America announces support for dental care benefits in health care reform bill

The health care reform bill passed by Congress, and now signed into law by President Obama, includes many provisions that will improve the nation's oral health. Most significantly, the bill does guarantee oral health coverage for children and allows for resources to extend oral disease prevention measures in every state. Over time, the bill's provisions can help to increase access to care for all ages.

27 Mar 2010

CHF applauds Congress and the President for introducing universal health care coverage

Children's Health Fund strongly supports the reconciliation bill signed by President Barack Obama implementing positive changes and fixes to the health reform bill he signed earlier this week. This second piece of health reform legislation marks an unprecedented effort to make real and positive change for the health and well-being of children in this country.

27 Mar 2010

Collegium Pharmaceutical files IND for second opioid product using DETERx technology

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has filed an Investigational New Drug application for COL-172, a tamper-resistant, extended-release oral opioid formulation intended to treat moderate to severe pain in individuals who require around-the-clock opioid therapy for an extended period of time.

26 Mar 2010

Medtronic announces enrollment of first European patients in randomized controlled trial of ITB Therapy

Medtronic, Inc. today announced the enrollment of the first European patients in the largest randomized controlled trial to date to investigate the benefits of ITB Therapy(R) (Intrathecal Baclofen) in post-stroke patients affected by spasticity. The announcement comes as the World Congress for Neurorehabilitation is taking place in Vienna, Austria.

26 Mar 2010

$UCSF study: Unusual femur fractures low in patients with osteoporosis$

UCSF study: Unusual femur fractures low in patients with osteoporosis

The occurrence of an unusual type of fracture of the femur, or the thigh bone, is very low in patients with osteoporosis, including those treated with the drug family known as bisphosphonates, according to a new study led by a team of UCSF epidemiologists.

26 Mar 2010

Diabetes reached epidemic proportions in adult population of China: Study

A large population-based study of diabetes in China conducted by investigators from Tulane University and their colleagues in China has concluded that the disease has reached epidemic proportions in the adult population of China. The study estimates that 92.4 million adults age 20 or older (9.7 percent of the population) have diabetes and 148.2 million adults (15.5 percent) have prediabetes, a key risk factor for the development of overt diabetes and cardiovascular disease.

26 Mar 2010

Oculus Innovative Sciences introduces Microcyn Dermatology HydroGel in the U.S.

Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today commercially introduced the Microcyn Dermatology HydroGel for the U.S. professional healthcare market.

26 Mar 2010

Oramed Pharmaceuticals completes Phase 2b study of ORMD-0801 oral insulin capsule

Oramed Pharmaceuticals Inc. announced today the completion of its' pivotal Phase 2b clinical study of its oral insulin capsule, ORMD-0801. The Company expects to report results from this study within the coming weeks.

26 Mar 2010

New research may help advance treatment strategies for common liver disease

A research article published in the journal PloS Pathogens could lead to improvements in the production of vaccines for hepatitis A, the most widespread viral disease in the world.

26 Mar 2010

Cook Medical to feature its Goldstein SonoBiopsy Catheter at 2010 AIUM convention

With over 10 million women in the U.S. suffering from endometrial disorders like abnormal uterine bleeding or uterine fibroids, the 2010 American Institute of Ultrasound Medicine convention will feature specialized programs and product showcases highlighting imaging solutions available to better diagnose these conditions.

26 Mar 2010

EVMS researchers awarded $1,076,250 grant to develop functional cure for Type 1 diabetes

Researchers at the Eastern Virginia Medical School Strelitz Diabetes Center have been awarded a $1,076,250 grant by the Department of Defense Peer Reviewed Medical Research Program to develop new ways of reversing the underlying causes of Type 1 diabetes.

26 Mar 2010

Oral News and Research

Genta reports net loss of $11.7M for fourth-quarter 2009

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

ARYx Therapeutics reports net loss of $5.8M for fourth-quarter 2009

IOF invites for Asia-Pacific Osteoporosis Meeting in Singapore

Cortex signs agreement to sell certain AMPAKINE compounds to Biovail

NZ Doctor struck off for misconduct

Cut in Medicare reimbursement to physicians will jeopardize timely surgical care

Two EMBEDA video news releases misleading, warns FDA DDMAC

Indoor tanning devices: AADA testifies before FDA panel on needed classification changes and calls for ban

Oral Health America announces support for dental care benefits in health care reform bill

CHF applauds Congress and the President for introducing universal health care coverage

Collegium Pharmaceutical files IND for second opioid product using DETERx technology

Medtronic announces enrollment of first European patients in randomized controlled trial of ITB Therapy

UCSF study: Unusual femur fractures low in patients with osteoporosis

Diabetes reached epidemic proportions in adult population of China: Study

Oculus Innovative Sciences introduces Microcyn Dermatology HydroGel in the U.S.

Oramed Pharmaceuticals completes Phase 2b study of ORMD-0801 oral insulin capsule

New research may help advance treatment strategies for common liver disease

Cook Medical to feature its Goldstein SonoBiopsy Catheter at 2010 AIUM convention

EVMS researchers awarded $1,076,250 grant to develop functional cure for Type 1 diabetes

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News